DVRG Archives - DirectorsTalk

Microsaic Systems collaboration with DeepVerge translating into early demand for Microsaic mass spectrometer units

21st October 2021

Microsaic Systems plc (LON:MSYS), has noted the update by DeepVerge plc (LON:DVRG) provided today regarding their orders for pathogen monitoring equipment for shipment this year to partners and customers in UK, India and China,

Be sure to check our sister interview main ratings news website

DVRG

Microsaic Systems collaboration with DeepVerge translating into early demand for Microsaic mass spectrometer units

Q&As

Cerillion’s Louis Hall on FY results, market potential and future outlook (LON:CER)

Ilika CEO highlights growth, Cirtec partnership and market opportunities (LON:IKA)

Dekel Agri-Vision’s Lincoln Moore on cashew growth and 2025 goals

Touchstone Exploration CEO on Cascadura results, Rio Claro block and 2025 plans (LON:TXP)

ICG Enterprise Trust: Strong portfolio growth, increased investments and resilient strategy

Firering Strategic Minerals targets Q4 commissioning and Limeco expansion (LON:FRG)

Funds

Building a strong data economy for Europe’s future

Real estate investment opportunity for diversified portfolios

Exploring opportunities in fixed income investments

Understanding tax reform and its impact

Volta Finance share price rises as performance returns hit 18.4% YTD (LON:VTA)

Emerging markets show positive momentum amid economic uncertainty

Presentations

Ilika plc: A New Era in Solid-State Battery Innovation – 2024 Investor Presentation

Time Finance PLC Strong Growth and Strategic Progress: A Message from CEO Ed Rimmer

Pulsar Helium Inc.: A Pioneering Force in the Helium Industry with High-Concentration Discoveries

Pennant International Maximising operational efficiency

Norcros Results Year ended 31 March 2024, Strategic Success and Sustainable Growth

SAE Renewables Future Strategy to 2035 and Investment Case by Graham Reid CEO

Broker Talk

Duke Capital: Unlocking growth with strategic equity raise

Volta Finance: Robust returns and discounted value highlight investment opportunity

Shield Therapeutics: Strong H1 ’24 Sales and Cashflow Outlook for H2 ’25

City of London Investment Company sees positive growth in Q4 and FY24 FUM

Expertise and strategic asset management in an under-supplied market

Global perspective and market positioning of pawnbroking for H&T Group